Neuroprotective Effects of Thiamine and Precursors with Higher Bioavailability: Focus on Benfotiamine and Dibenzoylthiamine by Sambon, Margaux et al.
 International Journal of 
Molecular Sciences
Review
Neuroprotective Effects of Thiamine and Precursors
with Higher Bioavailability: Focus on Benfotiamine
and Dibenzoylthiamine
Margaux Sambon, Pierre Wins and Lucien Bettendorff *


Citation: Sambon, M.; Wins, P.;
Bettendorff, L. Neuroprotective
Effects of Thiamine and Precursors
with Higher Bioavailability: Focus on
Benfotiamine and Dibenzoylthiamine.
Int. J. Mol. Sci. 2021, 22, 5418.
https://doi.org/10.3390/ijms22115418
Academic Editor: Elena Azzini
Received: 30 March 2021
Accepted: 18 May 2021
Published: 21 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
Laboratory of Neurophysiology, GIGA-Neurosciences University of Liège, 4000 Liège, Belgium;
margaux.sambon@gmail.com (M.S.); winspierre9@gmail.com (P.W.)
* Correspondence: L.Bettendorff@uliege.be; Tel.: +32-4-366-5967
Abstract: Thiamine (vitamin B1) is essential for brain function because of the coenzyme role of
thiamine diphosphate (ThDP) in glucose and energy metabolism. In order to compensate thiamine
deficiency, several thiamine precursors with higher bioavailability were developed since the 1950s.
Among these, the thioester benfotiamine (BFT) has been extensively studied and has beneficial
effects both in rodent models of neurodegeneration and in human clinical studies. BFT has antioxi-
dant and anti-inflammatory properties that seem to be mediated by a mechanism independent of
the coenzyme function of ThDP. BFT has no adverse effects and improves cognitive outcome in
patients with mild Alzheimer’s disease (AD). Recent in vitro studies show that another thiamine
thioester, dibenzoylthiamine (DBT) is even more efficient that BFT, especially with respect to its
anti-inflammatory potency. Thiamine thioesters have pleiotropic properties linked to an increase in
circulating thiamine concentrations and possibly in hitherto unidentified metabolites in particular
open thiazole ring derivatives. The identification of the active neuroprotective derivatives and the
clarification of their mechanism of action open extremely promising perspectives in the field of
neurodegenerative, neurodevelopmental and psychiatric conditions.
Keywords: thiamine diphosphate; neurodegeneration; neuroprotection; Alzheimer’s disease; oxida-
tive stress; diabetes; inflammation; glutathione; glycogen synthase kinase-3; transketolase
1. Introduction
Thiamine (vitamin B1), the first vitamin to be isolated [1], is an essential micronutrient
for all animal species. Thiamine deficiency (TD) is a life-threatening condition that, at
least in vertebrates, causes various disorders and lesions in nerves and brain. Early
investigations, starting at the end of the 19th century, led to the discovery that chronic
dietary TD caused the appearance of a polyneuritic syndrome called beriberi [2].
In the 1930s, Peters et al. [3] investigated the biochemical mechanisms of thiamine
function. For this, they used pigeons whose spastic head retraction (opisthotonus) is a
characteristic sign of acute TD. They showed that addition of the vitamin was required to
oxidize glucose and pyruvate in brain extracts from thiamine-deficient pigeons. It was later
found that the main active form of the vitamin was not free thiamine but its diphosphory-
lated form thiamine pyrophosphate (or diphosphate, ThDP) [3,4]. In the following years, it
was shown to act as a coenzyme for three essential enzymes or enzyme complexes: pyru-
vate dehydrogenase complex (PDHC), oxoglutarate dehydrogenase complex (OGDHC)
and transketolase (TKT) [5]. As these enzymes catalyze essential steps in glucose oxidation,
it is obvious that ThDP is an indispensable cofactor for energy metabolism (Figure 1) and
it is not surprising that TD will have deleterious effects on organs that are particularly
dependent on oxidative metabolism such as the nervous system and the heart. The mam-
malian brain is well known for its high consumption of glucose and oxygen. Moreover, the
ThDP-dependent enzyme complexes PDHC and OGDHC are required for the production
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of important neurotransmitters such as acetylcholine, glutamate or GABA (Figure 1) [6,7].
More recent studies have shown that ThDP is a cofactor for at least three other brain
enzymes (branched-chain 2-oxoacid dehydrogenase complex, 2-hydroxyacyl-CoA lyase 1
and 2-oxoadipate dehydrogenase complex), but their implications in TD disorders are less
obvious [8].
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Figure 1. Role of ThDP-dependent enzymes in cell metabolism. TKT, transketolase; PDHC py-
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These considerations have led to the widely accepted view that ThDP is the only ac-
tive cellular form of the vitamin and that disorders linked to TD are the consequence of a 
reduced activity of ThDP-dependent enzymes in the nervous system. However, TD-dis-
orders are complex and can adopt various forms [9]. Impairment of energy metabolism 
may be a satisfactory explanation for several syndromes such as some types of encepha-
lopathies or congestive heart failure observed in wet (the cardiac form of) beriberi. How-
ever, other features of TD disorders are more difficult to explain in view of their broad 
Figure 1. Role of ThDP-dependent nzymes in cell metabolis . TKT, transketol se; PDHC pyruvate dehydrogenase
complex; OGDHC, oxoglutarate dehydrogenase complex. Broken lines represent steps involving several reactions.
These considerations have led to the widely accepted view that ThDP is the only active
cellul r form of th vitamin and th t disor ers linked to TD are the consequence of a re-
duced acti ity of ThDP-dependent enzym s in the ne vous system. However, TD-disorders
are complex and can adopt various forms [9]. Impair ent of n gy metabolism may be
a satisfactory explanation for several syndromes such as some types of encephalopathies
or c ng stive heart failure observed in wet (the c rdiac form of) b rib ri. However, other
features of TD disorders are more difficult to explain in view of their broad clinical spec-
tr m [10]. In the brain, TD causes memory loss, disruption of blood– ain barrier as well
as inflammation (activation of glial cells) and oxidative stress [11–14].
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An even more disturbing feature is the selective vulnerability of diencephalic struc-
tures in the Wernicke–Korsakoff syndrome, a TD state caused mostly by heavy drink-
ing [15]. In Wernicke–Korsakoff’s syndrome, irreversible lesions appear in the thalamus
and mammillary bodies, while the cortex is largely spared. These observations have led to
the idea that thiamine (or a thiamine derivative other than ThDP) may exert neuromodu-
latory or neuroprotective actions through mechanisms unrelated to the coenzyme role of
ThDP [16–18].
TD and the resulting brain disorders are rather common in humans. This vulnerability
is linked to the slow carrier-mediated absorption of thiamine through the intestinal epithe-
lium [19] and the blood–brain barrier [20]. Indeed, thiamine is a water-soluble vitamin,
unable to cross biological membranes in the absence of a transport protein. Therefore,
precursors with higher bioavailability have been developed to increase the absorption of
the vitamin. Most of these precursors or provitamins are lipophilic compounds that freely
diffuse through cell membranes. Therefore, they can easily cross the intestinal epithelium
and reach the bloodstream. They are then readily converted to free thiamine and ThDP in
blood and liver. Therefore, oral treatment with such precursors may result in a rapid and
strong increase in blood thiamine levels.
Most of these thiamine precursors were developed in Japan in the 1950s and 1960s, the
best known are allithiamine, fursultiamine (thiamine tetrahydrofurfuryl disulfide, TTFD),
sulbutiamine (SuBT) and benfotiamine (BFT) (Figure 2) [21].
A most interesting and important point is that the usefulness of these compounds is
not restricted to relieving the symptoms of TD. Indeed, some of them have been shown
to extend beneficial effects (especially in the brain) in organisms having normal levels
of thiamine and ThDP. Interesting pharmacological properties were reported for SuBT
and TTFD, the former exerting antiasthenic properties [22] and the latter having some
beneficial effects in a mild autism spectrum disorder [23]. Presently, the most studied
precursor is BFT, which was initially shown to prevent several complications in models of
experimental diabetes [24] and also to exert prominent neuroprotective effects in mouse
models of neurodegeneration [25,26]. More importantly, it was recently shown that BFT
treatment in humans tends to improve cognitive outcome in patients with mild Alzheimer’s
disease (AD) [27,28]. In this review, we will focus on the mechanism of BFT actions
in vitro and in vivo. In addition, we will also highlight the neuroprotective effects of a
hitherto unexplored thiamine precursor, O,S-dibenzoylthiamine (DBT). This compound
has powerful antioxidant and anti-inflammatory properties similar to BFT but is active
at substantially lower concentrations [29]. Like BFT, DBT is devoid of toxic effects and
may have a therapeutic potential for brain pathologies associated with oxidative stress and
inflammation, i.e., neurodegenerative diseases and major depression.




Figure 2. Structural formulas of thiamine and thiamine precursors with higher bioavailability. The sulfur atom of the 
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in blue and the phosphate group on BFT is shown in red. Allithiamine, TTFD and SuBT (a symmetric dimer) are disulfides 
(boxes), while BFT, DBT and S-BT are thioesters. O-Benzoylthiamine results from the hydrolysis of the thioester in DBT or 
through an intramolecular rearrangement of S-BT followed by spontaneous thiazole ring closure. Note that for all the open 
thiazole ring derivatives the -CH3 group and the sulfur group must be in “trans” position to allow thiamine to be formed. 
This is the case for the (Z)-isomer of BFT shown here and which is the only one that should be called “benfotiamine”. 
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blue and the phosphate group on BFT is shown in red. Allithiamine, TTFD and SuBT (a symmetric dimer) are disulfides
(boxes), while BFT, DBT and S-BT are thioesters. O-Benzoylthiamine results from the hydrolysis of the thioester in DBT or
through an intramolecular rearrangement of S-BT followed by spontaneous thiazole ring closure. Note that for all the open
thiazole ring derivatives the -CH3 group and the sulfur group must be in “trans” position to allow thiamine to be formed.
This is the case for the (Z)-isomer of BFT shown here and which is the only one that should be called “benfotiamine”.
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2. Properties and Mechanism of Action of Benfotiamine
2.1. Structure and Physico-Chemical Properties of BFT
BFT (S-benzoylthiamine O-monophosphate, Figure 2) is an S-acyl (thioester) deriva-
tive with an open thiazole ring and a negatively charged phosphate group. Due to the
presence of the negatively charged phosphate group, BFT is practically insoluble in organic
solvents [30]. It is, however, soluble in water at slightly alkaline (but not acid) pH. There
can be two (E,Z) isomers differing by the substitution of the double C=C bond of the
thiazolium remnant. It is obvious that only the Z isomer can regenerate the thiazolium ring
characteristic of thiamine and hence only this isomer should be called “benfotiamine”.
BFT differs from another group of thiamine precursors, which are disulfides (allithi-
amine, SuBT, TTFD) and are uncharged hydrophobic compounds. Allithiamine is the
prototype of the thiamine disulfide prodrugs. D. Loew uses the term “allithiamine” to
designate all thiamine prodrugs with an open thiazole ring and that are converted to thi-
amine after closure of this ring [30]. However, and in agreement with D. Lonsdale [31], we
think that the term allithiamine should only be used for this compound, naturally formed
in crushed garlic bulbs [32] or, at most, be reserved to designate the group of thiamine
disulfides. In contrast, BFT and DBT are not disulfides but thioesters. This distinction is
very important, because both types of compounds have different pharmacological proper-
ties [29,33] and require different pathways for metabolization (Figure 3). Indeed, disulfides
require reduction (a redox reaction) by cellular thiols such as reduced glutathione (GSH) or
cysteine [30], while thioesters require hydrolysis to form the open thiamine thiol form.




Figure 3. Metabolization pathways of DBT, BFT and SuBT in an ideal cell. DBT: dibenzoylthiamine; BFT: benfotiamine; S-
BT: S-benzoylthiamine; SuBT: sulbutiamine; O-BT: O-benzoylthiamine; GSH: reduced glutathione; ThDP: thiamine di-
phosphate. Thiamine pyrophosphokinase (TPK), the enzyme responsible for ThDP synthesis is inhibited by its product 
ThDP by a feedback mechanism. In eukaryotes, ThMP can only be formed by hydrolysis of ThDP. As the metabolization 
reactions of DBT are not clear, we use broken lines. (Figure modified from [29]). 
DBT is also more effective as an anti-inflammatory agent than BFT. DBT (10–50 µM) 
protects BV2 cells from LPS-induced inflammatory processes (increased expression of 
iNOS and TNF-α and production of nitric oxide) by suppressing the translocation of NF-
κB into the nucleus. The same types of anti-inflammatory effects were observed with BFT 
(50 µM) but they were clearly weaker. 
Finally, chronic administration of DBT (30 mg/kg per day) arrested motor dysfunc-
tion in FUS transgenic mice, a model of amyotrophic lateral sclerosis, and relieved depres-
sive-like behavior in mice (25 mg/kg per day) submitted to chronic ultrasound stress [29]. 
Taken together, those data suggest that DBT has a therapeutic potential in brain pa-
thologies associated with oxidative stress and inflammation, not only in neurodegenera-
tive diseases, but also major depression and aggression linked to stressful events. 
4. Conclusions and Perspectives 
During the last 20 years, a number of studies have shown that BFT has powerful 
beneficial effects in animal models and brain pathologies, i.e., neurodegenerative diseases 
and stress-induced anxiety, aggression and depression. No toxic side-effects of this com-
pound have been reported. Recently, BFT treatment during 12 months resulted in im-
proved cognitive functions in patients with mild to moderate AD [27]. Thus, BFT may be 
considered as a potentially safe and cost-effective treatment for a number of brain dis-
eases. 
In spite of positive points, the therapeutic potential of BFT remains limited as, in an-
imal models, full beneficial actions require the administration of high doses (100–200 
mg/kg per day) for long periods. Since such high doses can hardly be used in humans, it 
is desirable to develop more potent compounds with similar beneficial actions. 
Figure 3. eta lizati at ays of DBT, BFT and SuBT in an ideal cell. DBT: dibenzoylthiamine; BFT: benfotiamine; S-BT:
S-benzoylthiamine; SuBT: sulbutiamine; O-BT: O-benzoylthiamine; GSH: reduced glutathione; ThDP: thiamine diphosphate.
Thiamine pyrophosphokinase (TPK), the enzyme responsible for ThDP synthesis is inhibited by its product ThDP by a
feedback mechanism. In eukaryotes, ThMP can only be formed by hydrolysis of ThDP. As the metabolization reactions of
DBT are not clear, we use broken lines. (Figure modified from [29]).
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2.2. Metabolism of BFT
BFT is a fairly stable polar compound that cannot diffuse through cell membranes as
it is not lipophilic (in contrast to what is claimed in many articles). However, after oral
administration, BFT can be rapidly dephosphorylated in the small intestine through the
action of alkaline phosphatases (ectoenzymes) bound to brush-borders of epithelial cells
(Figure 3) [30]. This yields S-benzoylthiamine (S-BT) which is the lipophilic metabolite
of BFT that easily diffuses through cell membranes and crosses the epithelium to reach
the blood stream. Its main products in human blood are thiamine and to a much lesser
extent ThMP and ThDP, mainly formed in erythrocytes [34]. Note that S-BT is not used
as a thiamine precursor as it is less stable than BFT. BFT has a higher bioavailability
than thiamine, thiamine disulfide or TTFD [30,35]. In humans, after a single dose, the
maximum thiamine concentration was dose-proportional and was reached after 1–2 h with
an elimination half-life of 6-14 h inversely depending on the dose. ThMP and ThDP have a
longer half-life, because they are formed and retained in erythrocytes, while thiamine is
mainly present in the plasma with the excess being eliminated by the kidneys [36]. Due to
the relatively long half-life, daily administration of BFT leads to an accumulation ratio of
~2, with a steady-state being reached at day 7 [34].
However, as most analytical methods are based on the detection of fluorescent
thiochrome derivative, only BFT metabolites with an intact thiazolium ring are detected [33].
Other metabolites would require the use of mass spectrometric detection [29,33,37,38].
Hence, the existence of presently unknown metabolites of BFT cannot be excluded (see
also Figure 3).
The requirement for dephosphorylation explains why oral administration of BFT is
more efficient than parenteral routes. However, it is not known what concentrations of
S-BT can be present in blood and what could be the half-life of S-BT in this compartment.
It is also unknown whether significant amounts of this compound might reach the brain
parenchyma. Indeed, no thiamine precursor has ever been reported to reach the brain.
In any event, probably most of the S-BT is hydrolyzed to thiamine after a few hours
through the action of thioesterases in red blood cells or in the liver. Note that the first
product of hydrolysis is the open thiol form of thiamine, but this form is quite unstable
at physiological pH (the equilibrium being towards the closed ring form [39]) and is
spontaneously converted to thiamine in the cytosol (Figure 3). In vitro, some S-BT may also
undergo a molecular rearrangement to O-benzoylthiamine (O-BT, Figures 2 and 3) [40], but
it is not known whether this conversion occurs in vivo.
In mice, oral treatment with BFT (100 mg/kg) strongly increases blood thiamine
concentrations, the maximum being reached two hours after gavage [41]. There is also a
rapid increase in thiamine and ThDP content in the liver, but not in the brain. Likewise,
the brain content of thiamine derivatives remains unchanged after chronic (14 days) oral
administration of BFT (100 mg/kg per day). Similar results were obtained when using
mouse models of brain disorders (see below). In these studies, the mice had been fed
on a thiamine-rich diet and brain ThDP content was not increased by BFT treatment. In
rats, however, a recent study found a significant elevation (30–50%) in ThDP content of
hippocampus and entorhinal cortex after 4-week treatment with BFT (150 mg/kg per
day) [42].
We studied the metabolism of BFT in more detail in cultured neuroblastoma cells [33].
Using mass spectrometric detection and HPLC, we confirmed that BFT is unable to cross
the cell membrane to a significant amount. We observed an increase in cell content of
thiamine only after a lag period, when BFT was dephosphorylated to S-BT by membrane-
bound phosphatases or serum phosphatases present in the culture medium. S-BT freely
diffuses into the cells where it is quickly converted to thiamine, presumably through the
action of intracellular thioesterases. A slower increase in cell ThDP content occurs, but
only a small part of the accumulated thiamine is converted to ThDP, a reaction catalyzed
by thiamine pyrophosphokinase (TPK, EC 2.7.6.2). This is because ThDP tends to block
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its own synthesis by a feedback mechanism (Figure 3) [43]. In eukaryotes, ThMP is only
formed by hydrolysis of ThDP.
2.3. Overview of the Beneficial Effects of BFT Treatment in Animal Models and Humans
Like other precursors such as allithiamine, thiamine disulfide, SuBT or TTFD, BFT
was first used to alleviate the symptoms of thiamine deficiency. It has long been known,
for instance, that patients with type 2 diabetes are often deficient in thiamine and that a
thiamine supplement is useful for the treatment of diabetic complications [44]. Thus, BFT
was first used to prevent the development of complications such as diabetic neuropathy
and retinopathy [24]. Other beneficial effects of BFT are the reduction of glucose toxicity in
endothelial cells [45], alleviation of diabetes-induced cerebral oxidative damage [46] and
rescue of cardiomyocyte contractile function in experimental diabetes [47].
In the following years, various neuroprotective effects of BFT treatment were reported
not only in diabetes-induced nerve damage but in various brain pathologies, particularly
in AD.
2.3.1. Beneficial Effects of BFT in Mouse Models of Brain Disorders
In a landmark study, Pan et al. (2010) [25] investigated the effects of chronic treatment
by BFT on amyloid precursor protein/presenilin (APP/PS1) double transgenic mice, a
classic model of AD. Oral treatment (100–200 mg/kg/day) during 8 weeks had powerful
beneficial effects on the animals, enhancing spatial memory as well as reducing amyloid
plaque numbers and phosphorylated tau levels in cortical areas. Remarkably, these ther-
apeutic actions were specific for BFT, and no such effects were seen when the mice were
treated with TTFD or high doses of thiamine.
More recently, a similar treatment with high doses of BFT (200 mg/kg per day for
8 weeks) was applied in a mouse model of tauopathy, P301S mice [26]. In this model, BFT
treatment increased lifespan, prevented death of spinal neurons and improved behavioral
deficits. It also decreased oxidative stress, inflammation, accumulation of advanced glyca-
tion end products (AGEs), tau phosphorylation and formation of neurofibrillary tangles in
cerebral cortex and hippocampus.
In addition to these therapeutic actions in mouse models of neurodegeneration, benefi-
cial effects of BFT have been reported in mouse models of stress-induced anxiety, aggression
and depression. Stress could be induced by a modified swim test, the presence of a preda-
tor for five consecutive nights [48,49] or chronic ultrasound exposure for 20 days [50]. In
those models, BFT treatment counteracted anxiety and depression-like behavior as well
as aggression linked to emotional stress. It also normalized plasticity markers, stimulated
neurogenesis and improved memory. These data suggest that BFT may have a therapeutic
potential not only in neurodegenerative diseases but also in other brain pathologies such
as major depression linked to stressful events.
2.3.2. BFT Treatment in Clinical Studies of Patients with Mild AD
Thiamine treatment does not exert significant beneficial effects in clinical trials of AD
even at very high doses (3 g per day for 3–12 months) [51,52]. This was ascribed to a poor
bioavailability of the vitamin and it was hoped that treatment with precursors of higher
bioavailability would give better therapeutic effects. A study carried out in 1996 with
TTFD (100 mg per day for 12 weeks) showed some improvement in cognitive function
in mildly impaired patients [53] but no follow-up study was done. The first clinical trial
of BFT treatment was conducted in 2016 on five patients with mild to moderate AD [28].
The patients, after receiving an oral dose of 300 mg of BFT per day during 18 months,
had improved cognitive function independently of β-amyloid accumulation. As there
were only five patients and no placebo control, these results could only be considered as
preliminary, but they showed that it was worth continuing to explore this track. More
recently, Gibson et al. [27] reported the results of a randomized placebo-controlled phase IIa
clinical trial of a 12 month BFT treatment of patients with either mild cognitive impairment
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or mild to moderate AD. The participants were treated with BFT (300 mg orally twice a
day) or placebo. In the blood of patients, there was a strong increase in concentrations of
thiamine and ThDP, while there was a significant reduction in blood advanced glycation
products (AGEs). Importantly, BFT treatment resulted in an improvement of cognitive
functions of patients as assessed by several tests. The results of this pilot study are very
encouraging and BFT appears to be a safe and cost-effective treatment of mild forms of AD.
In this clinical trial, as in a recent pharmacokinetic study (using doses up to 1200 mg, [34]),
no adverse effects of BFT were observed, suggesting that BFT is well tolerated and safe for
human use.
2.4. Mechanism of Action of Benfotiamine
2.4.1. Effects on Glucose Metabolism and Mitochondrial Function
The mechanism underlying the cytoprotective effects of BFT was first investigated
in diabetic pathologies. High glucose concentrations are believed to cause superoxide
overproduction by the mitochondrial electron transport chain as well as inactivation of
glyceraldehyde phosphate dehydrogenase, resulting in accumulation of glyceraldehyde 3-
phosphate and increased production of methylglyoxal and AGEs (Figure 1) [54]. In cultured
endothelial cells, BFT could block three major pathways of hyperglycemic damage [24]: the
hexosamine pathway, the AGE formation pathway and the diacylglycerol-protein kinase C
pathway. To explain those effects, the authors proposed that BFT administration causes a
removal of glyceraldehyde 3-phosphate and fructose 6-phosphate through activation of
TKT, a ThDP-dependent enzyme that catalyzes a rate-limiting step in the non-oxidative part
of the pentose phosphate pathway (Figure 1). BFT was thus supposed to act by increasing
intracellular ThDP levels. Likewise, several investigators considered that BFT might have
beneficial effects in neurodegenerative diseases as it could increase brain ThDP levels,
stimulating ThDP-dependent enzymes and boosting energy metabolism [55]. It is indeed
well known that disturbances in glucose metabolism are associated with the pathogenesis
of AD. This disease has even been considered as an “insulin-resistant brain state” [56]. On
the other hand, there are several common mechanisms associated with the neurological
symptoms observed in TD and AD, notably memory loss [14]. It has been known for a long
time that disturbances in ThDP-dependent steps in glucose metabolism are associated with
AD [57]. For instance, there is a significant decrease in OGDHC activity [58] and ThDP
content [59] in post mortem brains of AD patients. More recently, it was shown that TD
increases β-amyloid accumulation in the brains of AD mouse models [60].
Neuroprotective effects of BFT were tested for the first time in 2010 showing powerful
beneficial effects in a mouse model of AD [25], but this occurred without any concomitant
increase in brain ThDP content. Thus, the therapeutic actions of BFT do not appear to
be linked to a stimulation of glucose oxidative metabolism in this model. These findings
point to a specific pharmacological effect of BFT (more probably its metabolite S-BT) or a
presently unsuspected thiamine derivative.
In another investigation on the neuroprotective effects of BFT in a mouse model of
tauopathy, brain ThDP levels were also unchanged [26]. However, there was a significant
improvement of mitochondrial function, increasing respiratory complex I immunoreactivity
and superoxide dismutase activity. Interestingly, there was a marked upregulation of PGC-
1α mRNA levels, suggesting that BFT treatment stimulates mitochondrial biogenesis.
Mitochondrial dysfunction is involved in the onset and progression of neurodegenera-
tive diseases [61–64]. It is therefore likely that the beneficial effects of BFT administration
on mitochondrial function is not restricted to the activation of the ThDP-dependent enzyme
complexes PDHC and OGDHC. The mechanism of action of BFT metabolites on mitochon-
drial biogenesis and function remains largely unknown and deserves further investigation.
2.4.2. Effects of BFT on Glycogen Synthase Kinase 3 (GSK3)
GSK3 is a serine-threonine protein kinase originally identified as playing an important
role in glycogen metabolism. However, in the last two decades it became clear that GSK3 is
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a much more pleiotropic enzyme, able to phosphorylate over 100 substrates and to regulate
numerous cellular functions including gene transcription, apoptosis, neurodevelopment
and synaptic plasticity [65].
In mammals, there are two highly homologous isoforms of GSK3, α and β [66]. The
β isoform is expressed in higher levels in the brain (particularly the hippocampus) and
appears to be important for the regulation of neuronal function and plasticity [65,67–69].
GSK3β activity is regulated at different levels [70]. An important mechanism is its
inactivation through phosphorylation on serine 9, catalyzed by the kinase AKT. This occurs
when the prosurvival PI3K/AKT pathway is activated by insulin or growth factors [71,72].
Thus, neuronal survival is generally associated with downregulation of GSK3β activity.
As GSK3β touches so many aspects of cellular signaling, it is not surprising that
it is also involved in a huge number of pathological processes, including psychiatric
diseases and neurodegeneration. Indeed, several studies suggest that GSK3β is involved
in the pathogenesis of AD [73]. An obvious reason is that GSK3β is the predominant
kinase that phosphorylates tau, contributing to its hyperphosphorylation and generation of
neurofibrillary tangles [74]. Moreover, it has been found that inhibition of GSK3β activity
decreases the production and accumulation of amyloid-β in APP-overexpressing mice [75].
Recently, it was demonstrated that specific inhibition of GSK3β (but not of GSK3α) reduced
the BACE1-mediated cleavage of APP, reducing neuritic plaque formation and alleviating
memory deficits in an AD transgenic mouse model [76].
These findings are consistent with the idea that the reductions in amyloid load and
tau hyperphosphorylation caused by BFT treatment in APP/PS1 mice [25] could be linked
to the inhibition of GSK3α/β. These authors indeed found that BFT treatment decreased
the activity of GSK3, concomitant with an elevation of the phosphorylation level of the
enzyme. A BFT-induced elevation of GSK3α/β phosphorylation was also found in a rat
model of AD [42].
Abnormally active GSK3 has also been linked to the pathogenesis of mood disorders.
In knockin mice in which one or the other isoform of GSK3 was mutated to a hyperactive
form, those with hyperactive GSK3β (but not GSK3α) displayed heightened vulnerability
to the learned helplessness model of depression-like behavior [70]. Adult hippocampal
neurogenesis was also severely impaired. On the other hand, changes in expression and
phosphorylation of GSK3β were reported in mouse models of stress-induced anxiety and
depression [48]. In the prefrontal cortex, mRNA levels of GSK3β were increased in the
modified swim test and when the mice were exposed to predator stress. This increase was
fully reversed when the animals were treated with BFT (200 mg/kg per day).
Taken together, these findings suggest that the beneficial effects of BFT treatment in
mouse models of brain disease may involve a decrease of GSK3β activity. This decrease
seems to be mostly induced by phosphorylation of GSK3β on Ser 9 by AKT, though other
kinases may be involved. It should be mentioned, however, that in P301S mice (a model of
tauopathy), Tapias et al. did not find alterations in phospho-GSK3β expression in brain
following BFT treatment [26].
2.4.3. Possible Involvement of the PI3K/AKT Pathway in Neuroprotection by BFT
The PI3K/AKT pathway is well known to promote cell growth and the AKT protein
kinase appears to be a critical mediator of neuronal survival. It is thus conceivable that the
cytoprotective effects of BFT may involve the stimulation of this pathway. It was indeed
reported that BFT counteracts the toxic effects of high glucose in endothelial cells via
AKT/FoxO signaling [45]. In APP/PS1 mice, BFT increased the phosphorylation level of
AKT [25], thus increasing the activity of this kinase (that, in turn phosphorylates GSK3β).
Hence, BFT treatment can, at least to some extent, exert its neuroprotective effects
through a stimulation of the PI3K/AKT pathway, ultimately resulting in inhibition of
GSK3β. However, the molecular target of BFT treatment is not identified.
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2.4.4. Effects of BFT on the Accumulation of AGEs
Abnormal production of AGEs, a marker of impaired glucose metabolism, has been
reported to occur not only in type-2 diabetes but also in neurodegenerative diseases
such as AD [27,77] and mouse models of tauopathies [26]. Diabetic neuropathies and
retinopathies are linked to microvascular damage. In endothelial cells, BFT (50 µM) com-
pletely prevented the accumulation of AGEs induced by high glucose [24]. This protective
effect was abolished when the cells were transfected with transketolase (TKT) antisense
oligonucleotides, suggesting that BFT acts through activation of TKT, a ThDP-dependent
enzyme. The resulting upregulation of the pentose phosphate pathway would counteract
the hyperglycemia-induced accumulation of glyceraldehyde-3 phosphate, thus reducing
the production of methylglyoxal and AGEs.
In a mouse model of tauopathy BFT treatment was very effective to reduce AGE
formation in brain and spinal cord [26], but the role of TKT in the protective effect is less
clear. The authors reported a modest decrease of TKT activity in the brain of transgenic
mice compared to control mice. There was a slight but significant increase in TKT activity
in the brain of BFT-treated animals. It is not clear that such modest effects on TKT can
account for the strong effects of BFT treatment on AGE accumulation. In addition, there is
no evidence to show that the presence of AGEs in the transgenic mice might be linked to
hyperglycemia and elevation of glyceraldehyde 3-phosphate in brain tissues.
As mentioned above (Section 2.3.2) Gibson et al. (2020) demonstrated that BFT sig-
nificantly relieved the increase in AGEs in the blood of patients with mild AD during the
study, but TKT activity has not been studied [27].
2.4.5. Antioxidant Effects of BFT
A number of studies have suggested that thiamine and its derivatives may protect
the brain from oxidative damage. Indeed, oxidative stress is known to be associated with
TD [11,78]. On the other hand, it is well known that the brain is particularly vulnerable to
oxidative stress via its high oxygen consumption, and oxidative damage increases in the
aging brain, especially if neurodegeneration occurs. It was thus appealing to consider that
the beneficial effects of treatments with thiamine precursors in nerve and brain pathologies
may be linked, at least in part, to antioxidant effects.
An early publication suggested that BFT alleviates diabetes-induced cerebral oxidative
damage, independently of AGEs [46]. A more recent study showed that, in a mouse model
of anxiety and depression caused by predation stress, there is an increase of protein
carbonylation (a marker of oxidative stress) in the hippocampus of stressed mice. This
increase is fully reversed by treatment with BFT or high doses of thiamine [49]. Similar
results were reported with mice submitted to chronic ultrasound exposure [50].
In a transgenic mouse model of tauopathy, oxidative damage (lipid peroxidation) in
spinal cord sections is reversed by BFT (200 mg/mg per day) [26]. This treatment also
increases the expression of thioredoxin and some oxidative stress-protective enzymes
known to be under the control of the transcription factor Nrf2. Under normal conditions,
Nrf2 remains sequestered in the cytoplasm through its binding to Keap1. Reactive oxygen
species (ROS) or electrophilic compounds can react with Keap1 and dissociate it from Nrf2,
which can then diffuse to the nucleus, where it can bind to a promoter element called the
antioxidant response element (ARE). This activates the expression of a battery of genes
involved in protection against oxidative stress [79].
Tapias et al. [26] proposed a model in which putative products of BFT metabolism such
as S-BT and O-BT (Figure 1) would react with Keap1 and allow Nrf2 to enter the nucleus
and activate the expression of antioxidant genes. They indeed showed that, in embryonic
fibroblasts, BFT, S-BT and O-BT could stimulate the expression of Nrf2-dependent genes,
but only at very high concentrations (100 µM). It seems very unlikely that such high
concentrations of BFT metabolites can be reached in the brain parenchyma. In any event, it
should be recalled that, so far, no metabolite of BFT other than thiamine could be detected
in the blood, let alone in the brain.
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Antioxidant effects of BFT were also studied in vitro. In cultured neuroblastoma
cells, BFT (25–50 µM) protected the cells from paraquat-induced cell death [33]. Paraquat
is known to be toxic to many cell types, including neurons, through the production of
ROS, particularly superoxide anions. Paraquat increases protein carbonylation in mouse
neuroblastoma cells and this was relieved by BFT. The protective effects of BFT seem to be
linked to the accumulation of high concentrations of thiamine rather than the coenzyme
ThDP in the cells. However, the protection against ROS toxicity was not due to a direct
interaction of thiamine with ROS. It is thus likely that the protective effects of BFT are
linked to an indirect mechanism.
An obvious possibility is that the accumulation of intracellular thiamine might activate
the Nrf2/ARE pathway. However, this pathway was only weakly activated by BFT treat-
ment. This is not surprising as thiamine has only poor electrophilic properties and should
not easily react with Keap1 [26]. It could be argued that protection of the cells may be due
to the presence of intracellular S-BT, this metabolite of BFT being more likely to react with
Keap1 [26]. However, there is little accumulation of S-BT in the cytoplasm, as it is quickly
converted to thiamine by thioesterases. In addition, SuBT, a disulfide precursor of thiamine
which cannot be converted to S-BT (Figure 2) is practically as effective as BFT to protect the
cells from paraquat toxicity. These data are strong evidence that, in cultured neuroblastoma
cells, the active metabolite of BFT is thiamine, although it cannot be excluded that some
unknown metabolite of thiamine might be more active. Those in vitro studies also strongly
suggest that the stimulation of the Nrf2/ARE pathway is not sufficient to explain all the an-
tioxidant effects of BFT. Hence, alternative mechanisms should be explored. As mentioned
above, BFT treatment can improve mitochondrial biogenesis and function (increasing the
activity of superoxide dismutase) but the underlying mechanisms are unknown. On the
other hand, in BV2 microglial cells, BFT (50–250 µM) markedly increases the glutathione
content of the cells [80]. This suggests that enzymes of glutathione metabolism are possible
targets for the antioxidant actions of BFT. Microglial cells are resident macrophage-like
immune cells of the nervous system. Overactivation of microglia induces the production of
neurotoxic reactive oxygen and nitrogen species. This process is likely to play an important
role in neurodegenerative processes [81].
2.4.6. Anti-Inflammatory Effects of BFT
According to earlier studies (see [82]), TD is associated not only with oxidative stress
in brain but also with inflammatory processes such as microglial activation [83]. This raises
the possibility that thiamine precursors may exert anti-inflammatory actions. Indeed, BFT
treatment relieves inflammatory pain in rats [84]. P301S mice (a model of tauopathy) have
increased immunoreactivity of iNOS, COX-2, TNF-α and IL-1β in spinal cord neurons and
this was counteracted by chronic treatment with BFT [26].
The potential mechanism of the anti-inflammatory effects of BFT was studied in vitro.
In human macrophages treatment with lipopolysaccharide (LPS), a well-known inducer
of inflammation in these cells, caused the appearance of cytotoxic signals [85]. This
response was significantly suppressed in the presence of 100 µM BFT. BFT downregulated
proapoptotic signals and decreased the production of inflammatory marker proteins such
as iNOS and COX-2. Further, phosphorylation and degradation of IκB and consequent
activation and nuclear translocation of the transcription factor NF-κB were significantly
prevented by BFT.
In basal conditions, NF-κB is sequestered in the cytoplasm through binding to IκB.
When the inflammatory process is induced (e.g., by LPS), NF-κB separates from IκB and
can diffuse to the nucleus where it induces the expression of proinflammatory genes such
as iNOS and TNF-α. IκB is thus a possible target for an active metabolite of BFT.
BFT counteracts the morphological changes corresponding to the LPS-induced acti-
vation of the microglial cells. In addition, it decreases the production of proinflammatory
mediators such as iNOS, COX-2, TNF-α and IL6. These effects of BFT are likely mediated
by suppression of NF-κB translocation to the nucleus. BFT also suppresses phosphorylation
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of the kinases ERK1/2, JNK and AKT [86]. Another study suggested that BFT inhibits the
release of proinflammatory metabolites of arachidonic acid in macrophages [87].
However, all these effects require rather high concentrations (50–250 µM) of BFT and
they may thus not be relevant in vivo. Notwithstanding, thiamine administration in high
doses clearly has anti-inflammatory properties in vivo [88].
2.4.7. Effects of BFT on Glutamate Receptors, Synaptic Plasticity and Neurogenesis
Several studies have shown that BFT treatment can improve learning and memory
in mouse models of brain pathologies. This was the case in APP/PS1 mice, a model of
AD [25] and in P301S mice, a model of tauopathy [26]. These observations led to consider
the possibility that BFT treatment might increase the expression of NMDA receptors in
the brain. These receptors indeed play an essential role in memory formation in the
hippocampus and are altered in many brain pathologies including neurodegenerative
diseases and depression [89].
BFT treatment increases cognitive abilities in rats treated by intracerebroventricular
injections of streptozotocin, a model of AD. There was a simultaneous increase in the
expression of the NMDA-type-glutamate receptor subunit 2B (GluN2B) in hippocampus
and entorhinal cortex [42].
AMPA-type glutamate receptors are tetramers composed of subunits GluA1-4. They
mediate fast synaptic transmission involved in neuroplastic processes. In mice exposed
to chronic ultrasound exposure (resulting in aggressive behavior), Gorlova et al. reported
altered AMPA receptors subunits expression and decreased expression of plasticity markers
PSD95, PSA-NCAM and β-catenin [50]. The administration of thiamine or BFT (200 mg/kg
per day) decreased aggression, reversed ultrasound-induced changes in GluA1 and GluA2
subunit expression and reversed the decreased expression of plasticity markers.
The effect of BFT treatment on neurogenesis was studied in mice exposed to predator
stress for five consecutive nights. In this model, there is a marked, stress-induced, decrease
of proliferation (number of Ki67-positive cells) and survival (number of BrdU-positive
cells) of newborn immature neurons in the subgranular zone of the dentate gyrus. These
reductions were counteracted by treatment with thiamine or BFT, the latter being the most
effective [49].
3. Neuroprotective Properties of Dibenzoylthiamine
Though powerful beneficial effects of BFT treatment have been reported in mouse
models of neurodegeneration and other brain pathologies, this requires the administration
of high doses (100–200 mg/kg per day). If comparable, this would correspond to about 10 g
per day in humans. It may seem surprising, therefore, that a daily dose of 600 mg was ef-
fective to improve cognitive function in patients with moderate AD (see Section 2.3.2, [27]).
Though BFT has no significant side effects, it seems difficult to administer much higher
doses of BFT to patients. Therefore, there is a need to find precursors having beneficial
effects similar to BFT but acting at lower doses.
Recently, it was found that a hitherto unexplored derivative, DBT (Figure 1) could
meet these requirements [29]. DBT has actually been known for a long time and is allowed
as a food additive in Japan. No toxic or tumorigenic side effects have been reported [90],
yet there are practically no data about its biological effects. In salmon yearlings, it was
better tolerated than thiamine or BFT and it also led to a higher retention of thiamine over
time [91].
DBT is composed of a thiamine molecule with an open thiazolium ring linked to
two molecules of benzoate, one via a thioester the other via an O-ester bond. Hence, its
conversion to thiamine requires the action of two different enzymes: a thioesterase and
an esterase (Figure 3). DBT is lipophilic, yet it can be dissolved in water at slightly acid
pH. It strongly increases the intracellular thiamine concentrations, but there is almost
no formation of S-BT, one of the main degradation products of BFT. DBT (10 mg/kg,
intraperitoneal injection) increased the level of thiamine and ThDP in the blood of mice.
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The maximum levels were obtained after two hours. However, no significant increase of
ThDP level was observed in the liver or the brain of the animals [29].
In vitro studies showed that low (5–10 µM) concentrations of DBT protect neuroblas-
toma cells from paraquat toxicity by counteracting oxidative stress [29]. The concentrations
of BFT necessary to obtain the same protection were 5–10-fold higher (see Section 2.4.5).
Concerning the mechanisms involved, it was found that DBT increases the synthesis of
reduced glutathione and NADPH in a Nrf2-independent manner. As for BFT, these effects
also seem to be independent of the coenzyme role of ThDP.
DBT is also more effective as an anti-inflammatory agent than BFT. DBT (10–50 µM)
protects BV2 cells from LPS-induced inflammatory processes (increased expression of iNOS
and TNF-α and production of nitric oxide) by suppressing the translocation of NF-κB into
the nucleus. The same types of anti-inflammatory effects were observed with BFT (50 µM)
but they were clearly weaker.
Finally, chronic administration of DBT (30 mg/kg per day) arrested motor dysfunction
in FUS transgenic mice, a model of amyotrophic lateral sclerosis, and relieved depressive-
like behavior in mice (25 mg/kg per day) submitted to chronic ultrasound stress [29].
Taken together, those data suggest that DBT has a therapeutic potential in brain
pathologies associated with oxidative stress and inflammation, not only in neurodegenera-
tive diseases, but also major depression and aggression linked to stressful events.
4. Conclusions and Perspectives
During the last 20 years, a number of studies have shown that BFT has powerful bene-
ficial effects in animal models and brain pathologies, i.e., neurodegenerative diseases and
stress-induced anxiety, aggression and depression. No toxic side-effects of this compound
have been reported. Recently, BFT treatment during 12 months resulted in improved cogni-
tive functions in patients with mild to moderate AD [27]. Thus, BFT may be considered as
a potentially safe and cost-effective treatment for a number of brain diseases.
In spite of positive points, the therapeutic potential of BFT remains limited as, in ani-
mal models, full beneficial actions require the administration of high doses (100–200 mg/kg
per day) for long periods. Since such high doses can hardly be used in humans, it is desir-
able to develop more potent compounds with similar beneficial actions.
Recently, a very potent thiamine precursor, DBT, exerted antioxidant and anti-inflammatory
effects in vitro and in vivo at doses substantially lower than those required with BFT. Like
BFT, the compound appears to be devoid of toxic side effects. However, it remains to be
checked whether a prolonged use (e.g., as a therapy for AD patients for instance) would be
completely safe.
A very recent study showed a lowering of the Th-17 cell-mediated IL-17 response
by thiamine (200 mg per day for three weeks) in patients with elevated proinflammatory
cytokines and suggested the use of this vitamin to target the COVID-19 cytokine storm
observed in some patients [88]. We expect that DBT, because of its much higher anti-
inflammatory properties compared to thiamine [29], would be even more efficient.
The possibility of synergistic effects of thiamine with other validated drugs should
also be considered. For instance, a recent study found that coadministration of citicoline
(cytidine diphosphate-choline, an intermediate in the synthesis of phosphatidylcholine)
and BFT was more efficient than each compound alone in improving memory in the passive
avoidance test in a mouse model of streptozotocin-induced memory impairment [92].
A problem concerning the use of BFT and DBT is that, so far, their mechanisms of
action are not well understood. It has become rather obvious that these compounds do
not only act as thiamine precursors, i.e., by increasing blood thiamine concentrations
or brain ThDP levels. Indeed, they exert specific pharmacological effects that are not
mimicked by the administration of high doses of thiamine or even SuBT (which is not a
thioester but a disulfide that requires reduction, Figure 3) [22,29,33]. A recapitulation of
the properties and the effects of BFT and DBT is shown in Table 1. It is therefore likely
that unidentified metabolites are formed in blood or liver (possibly an open thiol form of
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thiamine, Figure 3) and that some of them can reach the central nervous system. In any
event, the concentrations of these active derivatives in the brain are probably very low and,
consequently, they would be very potent neuroprotective agents. It is therefore of primary
importance to identify these agents.
Table 1. Recapitulation of the properties and pharmacological effects of BFT and DBT.
Properties BFT DBT
Physicochemical properties
Solubility in organic solvents No Yes
Solubility in aqueous solutions Yes (pH > 8) Yes (pH < 6)
Metabolization
Enzymes [29,33] Ectophosphatases/thioesterases Estererases/thioesterases
Main metabolites [29,33] Thiamine, S-BT Thiamine, O-BT (?)
Pharmacological effects
Antioxidant effects
(Nrf2-independent) Yes (≤50 µM) [33]
Yes (≤50 µM)
(↑ GSH and NADPH) [29]
Anti-inflammatory effects
(probably via NF-κB) ↓ iNOS and TNF-α [29,86] ↓ iNOS and TNF-α [29]
Anti-AGEs effects ↓ In blood of AD patients [27] Not tested
Neuroprotective effects in
neurodegenerative diseases and models
Slows down cognitive decline in AD
patients [27,28]
Decreases β-amyloid load and tauopathy
in mouse model of AD [25]
Not tested in AD, but arrests motor
dysfunction in a mouse model of
amyotrophic lateral sclerosis, and relieves
depressive-like behavior in mice
submitted to chronic ultrasound stress
Effects on neuronal plasticity ↑ NMDAR AMPAR expression
1
↑ Neurogenesis 2 Not tested
Possible molecular targets
TKT Possibly increased activity [24] No effect [29]
GSK3β Inhibition by phosphorylation [25,42]Reduced expression [48] Not tested
PI3K/AKT pathway Activation [46] Not tested
Nrf-2 At concentrations > 100 µM [26] Not tested
NF-κB Inhibits LPS-induced nucleartranslocation [29,86]
Inhibits LPS-induced nuclear
translocation [29]
1 After stress-induced decrease in mouse models [42,50]; 2 after predator stress-induced suppression [49].
As BFT and DBT are administered orally, an alternative hypothesis might be an action
on the gut microbiota, by increasing the availability of thiamine to microorganisms in an en-
vironment with, otherwise, limited resources [93,94]. Indeed, a lot of recent research tends
to show that the gut microbiota are implicated in the etiopathogenesis or manifestation of
many neurodevelopmental, psychiatric and neurodegenerative diseases [95].
This leads to the conclusion that BFT and DBT have pleiotropic effects that can be
attributed to at least three modes of action: they strongly increase circulating thiamine
concentrations, they probably produce other specific metabolites or metabolites of thiamine
and they may favor growth of beneficial microorganisms of the gut microbiota.
The identification of the active derivatives of BFT and DBT and the clarification of
their mechanisms of action would open new avenues in the field of neuroprotection, with
the development of very potent and safe compounds for treating neurodegenerative and
other brain diseases.
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